Hims & Hers: Former Novo Nordisk Executive Sees "Long Future" in Selling Copycat Weight Loss Drugs and Joins the Board

Hims & Hers Health Inc. is adding Kåre Schultz, the longtime Novo Nordisk A/S executive, to its board after the company entered the booming weight-loss drug market, Bloomberg reports. Schultz, who spent more than 25 years at Novo Nordisk, including stints as president, vice CEO and COO, said in an interview that Hims has a "long future" in selling so-called compounded versions of blockbuster weight-loss drugs such as Wegovy and Zepbound, according to Bloomberg. Shortages of brand-name drugs from Novo and Eli Lilly & Co. have allowed...